Ionis Pharmaceuticals IONS Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months)?
- Ionis Pharmaceuticals (IONS) reported available-for-sale debt securities - unrealized loss position (<12 months) of $1.02B in Q1 2026.
- How has Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months) increased by 30.4% year-over-year, from $783.82M to $1.02B.
- What does available-for-sale debt securities - unrealized loss position (<12 months) mean?
- The value of debt investments currently worth less than their purchase price, held for under a year.
- How do you interpret available-for-sale debt securities - unrealized loss position (<12 months)?
- An increase indicates short-term market headwinds affecting the valuation of the company's liquid investment portfolio.
- How does available-for-sale debt securities - unrealized loss position (<12 months) compare across companies?
- Standard disclosure for companies maintaining high levels of marketable securities to fund R&D operations.